Sanofi US News

Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins

Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo

Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA

Data to be shared across multiple tumor types, including multiple myeloma, lung cancer and breast cancer

Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide

*Results demonstrate strong, but not universal, correlation between organ clinical responses and clinically meaningful improvements in patient-reported outcomes from a pooled analysis of ROCKstar and KD025-208 clinical trials

Results published today in the New England Journal of Medicine showed that treatment with rilzabrutinib resulted in a rapid and durable increase in platelet count in patients with heavily pretreated immune thrombocytopenia (ITP)

If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis